Bär & Karrer Advises Vifor Pharma on the Sale of OM Pharma
Vifor Pharma, a global leader in iron deficiency, nephrology and cardio-renal therapies, has sold its OM Pharma business, which primarily focuses on therapies for respiratory and urinary tract infections and is active in the treatment of vascular diseases, to Optimus Holding Ltd., a company founded by Etienne Jornod together with long-standing Swiss entrepreneurs and the Turkish pharmaceutical company Abdi Ibrahim. Closing of the transaction is expected to take place within the next weeks.
Bär & Karrer acts as legal advisor to Vifor Pharma in this transaction. The team includes Christoph Neeracher, Raphael Annasohn and Lukas Bründler (all M&A), Susanne Schreiber and Elena Kumashova (both Tax), Markus Wang (IP) as well as Mani Reinert (Antitrust).